Cytoo has launched its Cytooplates 96 cell normalisation technology, which is designed to bring robustness, sensitivity and powerful quantification to cell-based assays and high-content screening.
Cytooplates are suitable for pharma, biotech and academic screening centre customers employing high-content cell-based assays for research, drug safety and drug screening applications.
By restoring spatial information through the control of cell adhesions, Cytoo's adhesive micropattern technology normalises cell phenotypes.
Cell-to-cell variability is reduced and fewer cells are required to detect significant differences between conditions.
Cytooplates are glass-bottom, black-frame microplates presenting thousands of adhesive micropatterns per well, compatible with existing HCS equipment and automated microscopes.
The range will rapidly be extended to include the 384-well format.
Cytooplates complement Cytoo's initial Cytoochips offer of adhesive micropattern technology in a glass coverslip format.
The company believes that, for those involved in drug discovery, employing its technology will alleviate many of the current bottlenecks in HCS and lead to more hits and more meaningful data in cell-based screening, while enabling biologists to detect effects at much lower doses through the analysis of significantly fewer cells per condition.
This will ultimately translate into robust inter-platform standardisation, better leads, more predictive toxicology and higher productivity.
